Want to join the conversation?
$ABBV 2Q15 Call: The acquisition of Pharmacyclics will also drive strong financial benefits, further diversifying our revenue base significantly enhancing our revenue growth. We expect accretion related to the acquisition in excess of $0.60 per share in 2019 ramping to more than a dollar per share in 2021.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.